| Year |
Citation |
Score |
| 2018 |
Comer FI, Wang X, Yuan AQ, Muniz-Medina V, Sadowska A, Xu L, Perry S, Thompson P, Minter R, Woods R, Hinrichs MJ, Reed M, Affif-Rider S, Rebelatto M, Brown C, et al. Abstract LB-A20: Strategies to Improve the Safety and Efficacy of Biparatopic Antibody Drug Conjugates Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-A20 |
0.36 |
|
| 2017 |
Andres LM, Blong IW, Evans AC, Rumachik NG, Yamaguchi T, Pham ND, Thompson P, Kohler JJ, Bertozzi CR. Chemical modulation of protein O-GlcNAcylation via OGT inhibition promotes human neural cell differentiation. Acs Chemical Biology. PMID 28541657 DOI: 10.1021/Acschembio.7B00232 |
0.48 |
|
| 2016 |
Thompson P, Ezeadi E, Hutchinson I, Fleming R, Bezabeh B, Lin J, Mao S, Chen C, Masterson L, Zhong H, Toader D, Howard P, Wu H, Gao C, Dimasi N. Straightforward Glycoengineering Approach to Site-Specific Antibody-Pyrrolobenzodiazepine Conjugates. Acs Medicinal Chemistry Letters. 7: 1005-1008. PMID 27882199 DOI: 10.1021/Acsmedchemlett.6B00278 |
0.397 |
|
| 2016 |
Thompson P, Fleming R, Bezabeh B, Huang F, Mao S, Chen C, Harper J, Zhong H, Gao X, Yu XQ, Hinrichs MJ, Reed M, Kamal A, Strout P, Cho S, et al. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 27327768 DOI: 10.1016/J.Jconrel.2016.06.025 |
0.395 |
|
| 2016 |
Li J, Toader D, Perry SR, Muniz-Medina V, Wetzel L, Rebelatto MC, Hinrichs MJM, Fleming R, Bezabeh B, Thompson P, Dimasi N, Lam B, Yu X, Gao C, Dixit R, et al. Abstract 2970: MEDI4276, a HER2-targeting antibody tubulysin conjugate, displays potent invitroandin vivoactivity in preclinical studies Cancer Research. 76: 2970-2970. DOI: 10.1158/1538-7445.Am2016-2970 |
0.418 |
|
| 2015 |
Thompson P, Bezabeh B, Fleming R, Pruitt M, Mao S, Strout P, Chen C, Cho S, Zhong H, Wu H, Gao C, Dimasi N. Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody. Bioconjugate Chemistry. PMID 26340339 DOI: 10.1021/Acs.Bioconjchem.5B00355 |
0.379 |
|
| 2015 |
VanBrunt MP, Shanebeck K, Caldwell Z, Johnson J, Thompson P, Martin T, Dong H, Li G, Xu H, D'Hooge F, Masterson L, Bariola P, Tiberghien A, Ezeadi E, Williams DG, et al. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry. Bioconjugate Chemistry. PMID 26332743 DOI: 10.1021/Acs.Bioconjchem.5B00359 |
0.398 |
|
| 2015 |
Thompson P, Lakshminarayanan V, Supekar NT, Bradley JM, Cohen PA, Wolfert MA, Gendler SJ, Boons GJ. Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide. Chemical Communications (Cambridge, England). 51: 10214-7. PMID 26022217 DOI: 10.1039/C5Cc02199E |
0.541 |
|
| 2015 |
Toader D, Harper J, Lloyd C, Marwood R, Bannister D, Mao S, Chen C(, Zhong H(, Bedian V, Wang F, Gingipalli L, Vasbinder M, Thompson P, Fleming R, Bezabeh B, et al. Abstract B170: Discovery of tubulysin payloads for antibody drug conjugates with potentin vitroactivityandin vivoefficacy in solid tumor models Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B170 |
0.433 |
|
| 2015 |
Cai X, Globisch D, Thompson P, Lin J, Toader D, Dimasi N, Gao C, Janda KD. Corrigendum to "A chemoenzymatic approach toward the preparation of site-specific antibody-drug conjugates" [Tetrahedron Lett. 56 (2015) 3172-3175] Tetrahedron Letters. DOI: 10.1016/J.Tetlet.2015.06.088 |
0.319 |
|
| 2014 |
Abdel-Aal AB, Lakshminarayanan V, Thompson P, Supekar N, Bradley JM, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. Chembiochem : a European Journal of Chemical Biology. 15: 1508-13. PMID 24890740 DOI: 10.1002/Cbic.201402077 |
0.569 |
|
| 2012 |
Borgert A, Heimburg-Molinaro J, Song X, Lasanajak Y, Ju T, Liu M, Thompson P, Ragupathi G, Barany G, Smith DF, Cummings RD, Live D. Deciphering structural elements of mucin glycoprotein recognition. Acs Chemical Biology. 7: 1031-9. PMID 22444368 DOI: 10.1021/Cb300076S |
0.31 |
|
| 2012 |
Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proceedings of the National Academy of Sciences of the United States of America. 109: 261-6. PMID 22171012 DOI: 10.1073/Pnas.1115166109 |
0.581 |
|
| 2009 |
Buskas T, Thompson P, Boons GJ. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. Chemical Communications (Cambridge, England). 5335-49. PMID 19724783 DOI: 10.1039/B908664C |
0.537 |
|
| Show low-probability matches. |